Filing Flows › Immucell (ICCC) › R&D spending
Immucell (ICCC) R&D spending by quarter
Immucell's R&D spending was $318K in Q1 2026 (first quarter 2026), -58% from Q4 2025. Over the last 6 quarters it ranged from $318K (Q1 2026) to $832K (Q2 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q1 2026 | $318K | -58% | -58% |
| Q4 2025 | $759K | +9% | -7% |
| Q3 2025 | $694K | -17% | — |
| Q2 2025 | $832K | +10% | — |
| Q1 2025 | $757K | -8% | — |
| Q4 2024 | $819K | — | — |
Q1 2026 at a glance
Immucell, Q1 2026: revenue $10.4M (+28% year over year), operating margin 19.0%, net earnings $1.9M, operating cash flow $3.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Immucell's R&D spending?
Immucell's R&D spending was $318K in Q1 2026 (first quarter 2026), -58% from Q4 2025.
How has Immucell's R&D spending changed?
Over the last 6 quarters it ranged from $318K (Q1 2026) to $832K (Q2 2025).